📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-07-24 17:48
0 analysed today
FollowTelegram
0
Today
153,423
All-time analysed
44,082
Positive
6,813
Negative
93,584
Neutral
8,876
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
4 announcements match the current filters (relevance ≥ 5).
Astonea Labs FY26 Revenue Grows 51% to ₹147 Cr; Board Approves New Subsidiaries and MOA Expansion
Astonea Labs reported a consolidated revenue of ₹147 Cr for FY26, representing a 51.5% growth over FY25's ₹97 Cr. Despite the top-line surge, consolidated net profit for FY26 stood at ₹4 Cr, a decline from ₹5 Cr in the previous year, indicating margin pressure. The Board has approved a significant expansion of the company's business objects to include e-commerce, nutraceuticals, and ayurvedic products. Additionally, the company plans to incorporate new subsidiaries to facilitate focused business operations and long-term growth.
Confidence: HIGH
What changedThe company has finalized its delayed consolidated FY26 results and formally pivoted its business strategy to include digital distribution and a broader range of healthcare products.
Why it mattersThe 51% revenue growth indicates strong market scaling, but the delay in consolidated results (due to associate company Damaira Pharmaceuticals) and the PAT dip suggest operational or associate-level headwinds that need monitoring.
FY26 Consolidated Revenue: ₹147 CrFY26 Revenue Growth vs FY25: 51.5%FY26 Consolidated Net Profit: ₹4 CrDebt-to-Equity Ratio: 0.74AGM Date: 21st August, 2026
📅 Short termThe market is likely to view the strong revenue growth positively, though the slight decline in annual PAT may cap gains until margin clarity emerges.
📈 Long termThe expansion into nutraceuticals and e-commerce, combined with a subsidiary-led growth model, suggests a structural shift toward a more diversified and digitally-enabled pharma player.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Margin compression (PAT fell despite 51% revenue growth)
- Dependency on associate company (Damaira Pharmaceuticals) for consolidated reporting
- Execution risk in new e-commerce and subsidiary ventures
Key Highlights
FY26 Consolidated Revenue reached ₹147 Cr, up from ₹97 Cr in FY25 (51.5% growth)
H2 FY26 Revenue of ₹81 Cr showed sequential growth over H1 FY26's ₹66 Cr
Board approved incorporation of one or more wholly-owned subsidiaries in India for business expansion
Object Clause of MOA altered to include e-commerce, digital marketplaces, and nutraceuticals
9th Annual General Meeting (AGM) scheduled for August 21, 2026
👀 What to Watch
Investors should monitor the margin profile in upcoming quarters to see if the revenue growth translates into better profitability, and track the execution of the new e-commerce and subsidiary strategies.
Astonea Labs Approves FY26 Consolidated Results and Plans New Subsidiaries
Astonea Labs has approved its audited consolidated financial results for the year ended March 31, 2026, which were previously delayed from May 2026 due to pending audits of its associate, Damaira Pharmaceuticals. The board also approved the incorporation of new subsidiaries in India to expand business segments and proposed altering the Memorandum of Association (MOA) to include e-commerce and digital marketplace distribution. The 9th Annual General Meeting (AGM) is scheduled for August 21, 2026, to seek shareholder approval for these changes.
Confidence: HIGH
What changedThe company has finalized its consolidated financial reporting for FY26 and formally initiated a strategy to expand through new subsidiaries and digital distribution channels.
Why it mattersThe finalization of consolidated accounts provides a complete view of the company's financial health including its associates; the MOA changes indicate a strategic pivot toward modern retail and e-commerce channels.
AGM Date: August 21, 2026FY25 Revenue: ₹97.0 crMar 2026 Quarterly Revenue: ₹81.0 crDebt: ₹43 crNet Worth: ₹58 cr
📅 Short termThe market will likely focus on the finalized consolidated numbers and the upcoming AGM details in the next few weeks.
📈 Long termThe long-term impact depends on the successful execution of the new subsidiary strategy and the company's ability to scale its presence in the e-commerce and digital marketplace segments.
⚠ Risk flags
- Reporting delay due to associate company audit
- Potential capital requirements for new subsidiaries
- Execution risk in entering new digital distribution channels
Key Highlights
Consolidated FY26 results approved after a delay from the original May 30, 2026 board meeting
9th Annual General Meeting scheduled for August 21, 2026, at 11:30 A.M. in Chandigarh
Proposed alteration of MOA Object Clause to include manufacturing and retail via e-commerce and digital platforms
Board approval for incorporation and investment in one or more wholly-owned subsidiaries in India
Re-appointment of Ms. Pooja Singh as Director recommended for shareholder approval
👀 What to Watch
Investors should review the consolidated financial statements once published to assess the performance of the associate company, Damaira Pharmaceuticals, and monitor future disclosures regarding the capital outlay for new subsidiaries.
Board Meeting on July 24 to Approve FY26 Consolidated Results and New Subsidiary
Astonea Labs has scheduled a board meeting for July 24, 2026, to approve its audited consolidated financial results for the fiscal year ended March 31, 2026. This follows the approval of standalone results earlier on May 30, 2026. Beyond financials, the board will consider two strategic items: the incorporation of a new subsidiary or wholly-owned subsidiary in India and an alteration to the Memorandum of Association (MOA). The meeting will also finalize the notice for the company's 9th Annual General Meeting.
Confidence: HIGH
What changedThe company is moving to finalize its consolidated financial reporting for FY26 and is initiating the setup of a new corporate subsidiary.
Why it mattersConsolidated results provide the full financial picture of the group; the addition of a subsidiary and MOA changes suggest a strategic expansion or structural shift in the business.
Board Meeting Date: July 24, 2026Standalone Results Approved: May 30, 2026Trading Window Closed Since: April 1, 2026AGM Number: 9th
📅 Short termThe stock may see activity around July 24 as the market reacts to the consolidated earnings and details of the new subsidiary.
📈 Long termThe formation of a subsidiary indicates long-term expansion plans, though the impact will depend on the capital allocation and business focus of the new entity.
⚠ Risk flags
- Lack of detail on the nature of the new subsidiary
- Unspecified changes to the Memorandum of Association
Key Highlights
Board meeting scheduled for July 24, 2026, to approve FY26 consolidated results
Standalone results for FY26 were previously approved on May 30, 2026
Proposal to incorporate and invest in a new Subsidiary or Wholly Owned Subsidiary in India
Proposed alteration of the Memorandum of Association (MOA) to be considered
Trading window has been closed since April 1, 2026, and will reopen 48 hours after the results
👀 What to Watch
Investors should watch for the July 24 announcement to understand the purpose of the new subsidiary and the specific changes to the MOA, which may signal new business directions.
Astonea Labs Receives SBDMA Yemen Certification for Panchkula Manufacturing Facility
Astonea Labs Ltd has successfully completed a regulatory inspection of its manufacturing facility located in Panchkula, Haryana. The inspection was conducted by the Supreme Board of Drugs and Medical Appliances (SBDMA), Ministry of Health and Population, Republic of Yemen. The company received the official certificate on July 14, 2026, confirming compliance with the required standards. This certification is a critical step for the company to export its pharmaceutical products to the Yemen market.
Confidence: HIGH
What changedThe company's Panchkula manufacturing facility has gained formal regulatory approval from Yemen's health ministry, transitioning from a pending inspection status to a certified status for that region.
Why it mattersInternational regulatory approvals are essential for pharmaceutical companies to expand their geographic footprint. This certification validates the company's manufacturing standards and opens up a specific export market.
Date of Certification: July 14, 2026Facility Location: Panchkula, Haryana
📅 Short termThe news is likely to be viewed positively by the market as it demonstrates regulatory compliance and potential for export growth.
📈 Long termWhile this specific certification is for Yemen, it contributes to the company's broader strategy of building an export-oriented pharmaceutical business. Long-term impact depends on the volume of business generated from this market.
⚠ Risk flags
- Geopolitical stability in the export destination (Yemen)
- Currency fluctuation risks associated with international trade
Key Highlights
Successful completion of inspection by SBDMA, Republic of Yemen, on July 14, 2026
Manufacturing facility located at Village Haripur, Panchkula, Haryana - 134204
Official certificate received from the regulatory authority confirming compliance
Enables the company to register and export pharmaceutical products to Yemen
👀 What to Watch
Monitor upcoming quarterly results for any increase in export revenue or specific mentions of order wins from the Middle East region following this certification.
